Nothing Special   »   [go: up one dir, main page]

SG11202101735PA - Teleost invariant chain cancer vaccine - Google Patents

Teleost invariant chain cancer vaccine

Info

Publication number
SG11202101735PA
SG11202101735PA SG11202101735PA SG11202101735PA SG11202101735PA SG 11202101735P A SG11202101735P A SG 11202101735PA SG 11202101735P A SG11202101735P A SG 11202101735PA SG 11202101735P A SG11202101735P A SG 11202101735PA SG 11202101735P A SG11202101735P A SG 11202101735PA
Authority
SG
Singapore
Prior art keywords
cancer vaccine
invariant chain
teleost
chain cancer
teleost invariant
Prior art date
Application number
SG11202101735PA
Inventor
Alfredo Nicosia
Elisa Scarselli
Armin Lahm
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of SG11202101735PA publication Critical patent/SG11202101735PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4213—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202101735PA 2018-10-19 2019-10-18 Teleost invariant chain cancer vaccine SG11202101735PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18201541 2018-10-19
PCT/EP2019/078395 WO2020079234A1 (en) 2018-10-19 2019-10-18 Teleost invariant chain cancer vaccine

Publications (1)

Publication Number Publication Date
SG11202101735PA true SG11202101735PA (en) 2021-03-30

Family

ID=64270581

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101735PA SG11202101735PA (en) 2018-10-19 2019-10-18 Teleost invariant chain cancer vaccine

Country Status (12)

Country Link
US (1) US20210379169A1 (en)
EP (1) EP3866848A1 (en)
JP (2) JP7638526B2 (en)
KR (1) KR20210081325A (en)
CN (1) CN112955177B (en)
AU (1) AU2019361280A1 (en)
BR (1) BR112021003499A2 (en)
CA (1) CA3109541A1 (en)
IL (1) IL282429B2 (en)
MX (1) MX2021004425A (en)
SG (1) SG11202101735PA (en)
WO (1) WO2020079234A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852977B (en) 2019-01-10 2024-08-21 美商健生生物科技公司 Prostate neoantigens and their uses
CN114980920A (en) 2019-11-18 2022-08-30 詹森生物科技公司 Vaccine based on mutant CALR and JAK2 and uses thereof
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines
AR132344A1 (en) * 2023-04-10 2025-06-18 Medimmune Llc OPTIMIZATION OF CD3 ANTIGEN BINDING DOMAINS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711518B1 (en) 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Chimpanzee adenovirus vaccine carriers
WO2010057501A1 (en) 2008-11-21 2010-05-27 Københavns Universitet (University Of Copenhagen) Priming of an immune response
NZ594355A (en) 2009-02-02 2012-11-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
JP7289265B2 (en) * 2016-10-26 2023-06-09 キュアバック エスイー Lipid nanoparticle mRNA vaccine
SG11202003799RA (en) * 2017-11-03 2020-05-28 Nouscom Ag Vaccine t cell enhancer

Also Published As

Publication number Publication date
JP2022504315A (en) 2022-01-13
WO2020079234A1 (en) 2020-04-23
CN112955177A (en) 2021-06-11
JP2024059879A (en) 2024-05-01
US20210379169A1 (en) 2021-12-09
CA3109541A1 (en) 2020-04-23
CN112955177B (en) 2024-10-25
KR20210081325A (en) 2021-07-01
BR112021003499A2 (en) 2021-05-18
AU2019361280A1 (en) 2021-03-11
JP7638526B2 (en) 2025-03-04
EP3866848A1 (en) 2021-08-25
IL282429A (en) 2021-06-30
MX2021004425A (en) 2021-07-06
IL282429B2 (en) 2025-04-01
IL282429B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
IL264023A (en) NANT vaccine for cancer
PL3600409T3 (en) T-CELL RECEPTORS AND IMMUNE THERAPY USING THEM AGAINST PRAME-POSITIVE CANCER
SG11202101735PA (en) Teleost invariant chain cancer vaccine
IL261468A (en) Uterine cancer treatments
EP3576751A4 (en) RNA CANCER VACCINES
EP3651772A4 (en) COMBINATION CANCER THERAPY
SI3283527T1 (en) Combination therapy against cancer
IL263123A (en) Cancer treatments
IL268463A (en) Cancer treatment
EP3413927A4 (en) Cancer Therapy
EP3546020A4 (en) CANCER TREATMENT DEVICE
GB201820660D0 (en) Cancer treatments
IL292272A (en) Cancer vaccine
EP3785729C0 (en) VACCINES AGAINST OVARIAN CANCER
EP3675891A4 (en) COMBINATION CANCER THERAPY
EP3576791A4 (en) CALRETICULIN-MEDIATED CANCER TREATMENT
SI3405212T1 (en) Cancer vaccines
EP3765067C0 (en) AUTOLOGOUS CANCER VACCINE
GB201814487D0 (en) Cancer
GB201800733D0 (en) Cancer
GB2546773B (en) Cancer
IL260988A (en) ptps-based vaccines against cancer
IL280112A (en) Cancer vaccines for breast cancer
HK40059064A (en) Teleost invariant chain cancer vaccine
GB201811382D0 (en) Vaccine